JO
TARS icon

John Overdeck’s Tarsus Pharmaceuticals TARS Stock Holding History

John Overdeck’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27M Buy
36,038
+16,960
+89% +$1.08M ﹤0.01% 2876
2026
Q1 		$1.34M Hold
19,078
– – ﹤0.01% 3042
2025
Q4 		$1.56M Buy
19,078
+9,100
+91% +$679K ﹤0.01% 2622
2025
Q3 		$593K Sell
9,978
-9,047
-48% -$445K ﹤0.01% 2901
2025
Q2 		$771K Sell
19,025
-10,257
-35% -$462K ﹤0.01% 2379
2025
Q1 		$1.5M Sell
29,282
-61,889
-68% -$3.06M ﹤0.01% 1925
2024
Q4 		$5.05M Sell
91,171
-204,832
-69% -$9.3M 0.01% 1096
2024
Q3 		$9.74M Sell
296,003
-138,339
-32% -$3.89M 0.02% 771
2024
Q2 		$11.8M Buy
434,342
+286,516
+194% +$9.63M 0.03% 651
2024
Q1 		$5.37M Buy
147,826
+75,886
+105% +$2.23M 0.01% 937
2023
Q4 		$1.46M Buy
71,940
+17,842
+33% +$298K ﹤0.01% 1838
2023
Q3 		$961K Buy
54,098
+4,628
+9% +$81.9K ﹤0.01% 1961
2023
Q2 		$894K Buy
+49,470
New +$787K ﹤0.01% 2000
2022
Q4 		– Sell
-18,851
Closed -$323K – 3077
2022
Q3 		$323K Sell
18,851
-6,868
-27% -$109K ﹤0.01% 1943
2022
Q2 		$375K Buy
+25,719
New +$386K ﹤0.01% 1933

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's TARS Position: Q2 2026 in Review

John Overdeck increased its Tarsus Pharmaceuticals (TARS) stake by 89% in Q2 2026, buying an estimated $1.08M and bringing the position to 36,038 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2876.

John Overdeck first reported a position in TARS in Q2 2022 and has held it in 15 quarters since. The position peaked at $11.8M in Q2 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • John Overdeck held 36,038 shares of Tarsus Pharmaceuticals worth $2.27M as of Q2 2026.
  • John Overdeck bought 16,960 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.08M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2876 holding.
  • John Overdeck first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • John Overdeck's Tarsus Pharmaceuticals position peaked at $11.8M in Q2 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.